Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib - Top-Institutions - MDSpire

Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib

  • By

  • Jean-Claude Tardif

  • Marc A Pfeffer

  • Simon Kouz

  • Wolfgang Koenig

  • Aldo P Maggioni

  • John J V McMurray

  • David D Waters

  • J Wouter Jukema

  • Harvey D White

  • Therese Heinonen

  • David Kallend

  • Fouzia Laghrissi-Thode

  • Valtteri Muroke

  • Annik Fortier

  • Marie-Claude Guertin

  • Marie-Pierre Dubé

  • for the dal-GenE Investigators

  • October 14, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Cardiovascular Genetics
    • Precision Medicine

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Cardiovascular Genetics

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Genomic Medicine

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Genetics

  • #5

    Stanford University Medical Center
    Stanford University Medical Center

    Stanford, CA

    Key Differentiators

    • Cardiology
    • Genomic Medicine

Original Source(s)

Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib

  • by Jean-Claude Tardif, Marc A Pfeffer, Simon Kouz, Wolfgang Koenig, Aldo P Maggioni, John J V McMurray, David D Waters, J Wouter Jukema, Harvey D White, Therese Heinonen, David Kallend, Fouzia Laghrissi-Thode, Valtteri Muroke, Annik Fortier, Marie-Claude Guertin, Marie-Pierre Dubé, for the dal-GenE Investigators

  • October 14, 2025

Related Content

Putting a POC Troponin to the Test

Independent verification shows strong precision and concordance with lab assays across clinical thresholds.

Staffing, Flexibility Top Nurses' List to Return

Two-thirds of former hospital nurses would consider coming back if workplace conditions improved, survey finds

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.